Cat. No.: HY-N0545

Taurocholic acid sodium

(Synonyms: Sodium taurocholate; N-Choloyltaurine sodium)

34 Cited Publications

Customer Review

Based on 34 publication(s) in Google Scholar

Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 145-42-6
Formula: C₂₆H₄₄NNaO₇S
Molecular Weight:537.68

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Taurocholic acid sodium Chemical Structure

CAS No.: 145-42-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Induced Disease Models
Chemical Information
Publications (34)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

All VEGFR Isoforms :

All Endogenous Metabolite Isoforms :

In Vitro

Taurocholic acid (100 μM, 24 h) sodium decreases the proportion of CD3+CD8+ T and NK cells in isolated PBMCs from HBeAg-positive CHB patients^[2].
Taurocholic acid (100 μM, 24 h) sodium decreases IFN-α stimulated cytokine and cytotoxic granule levels (IFN-γ, TNF-α, granzyme B) in CD3+CD8+ T and NK cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) sodium promotes HBV replication by reducing the percentage of NK and CD3+CD8+ T cells in C57BL/6 mice with tail vein injection with rAAV8-1.3HBV^[2].
Taurocholic acid (1% in diet, 1 week) sodium prevents hepatic artery ligation (HAL)-induced cholangiocyte damage in rats by upregulation of VEGF-A expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice^[2]
Dosage:

100 mg/kg
Administration:

oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks
Result:

Reduced the percentage of NK and CD3+CD8+ T cells.
Increases serum HBsAg, HBeAg, and HBV DNA levels.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Taurocholic acid can be used in animal modeling to create stress-induced gastric injury models and pancreatitis models^[3]^[4]^[5].

1. Induction of stress-induced gastric injury^[3]

Background

Both in humans and experimental animals, Taurocholic acid irritates the gastric mucosa and causes the reverse diffusion of acid through the broken barrier.

Specific Modeling Methods

Rat: Donryu strain rats • male • 230-240 g &bull
Administration: 30-300 mg/kg • p.o • single dose.

Note

After rats have fasted for 24 hours, their pylorus is ligated under ether anesthesia. Fifteen minutes after pylorus ligation, medication is administered to the rats.
The pylorus-ligated rats are then placed in cages with restricted movement.
Subsequently, the cages are immersed in a water bath maintained at 23°C until the water level reaches the xiphoid process of the rats, lasting for 7 hours.
Seven hours later, the animals are sacrificed under ether anesthesia, and the stomach of each animal is removed. The gastric contents are collected through the esophagus and analyzed for volume and acidity.

Modeling Indicators

Molecular Changes: Significant reductions in acidity and pepsin activity were observed, along with an increase in Na⁺ concentration. However, there was no effect on gastric juice volume or K⁺ concentration.

Correlated Product(s): Aspirin (HY-14654)

Opposite Product(s): L-Glutamine (HY-N0390)

2. Induction of Acute Pancreatitis^[4].

Background

Taurocholic acid induced the formation of interstitial edema and caused acinar cell vacuolization in the pancreatic lobules. Taurocholic acid also increased serum amylase and lipase activities. Interstitial edema becomes one of the most important criteria for assessing pancreatic damage in acute pancreatitis^[4].

Specific Modeling Methods

Rat: Wistar• male • weighing 220-240 g^[1]
Administration: 1 mL/kg• retrograde infusion into the common pancreaticobiliary duct• at a speed of 0.25 mL/min^[4]
Mice: Balb/c and Wistar• male • weighing 25-30 g and 250-300 g^[5]
Administration: 1 mL/kg• retrograde infusion• perfusion for 8 h^[5]

Note

(1) Before administration, mice were kept at room temperature of 23±1°C and 50-60 % relative humidity with free access to water and chow on a 12-h light/dark cycle. They were allowed to adapt to this environment for 5 days before the experiment, and received no nourishment and free access to water for 12 h preoperatively^[1]^[2].
(2) Pancreatic acinar cells were isolated freshly from Balb/c or C57/BL6J mice using a collagenase IV. Cells were treated under room temperature, and used within 4 hours after isolation^[2].

Modeling Indicators

b>Histological analysis: Taurocholic acid administration caused the formation of interstitial edema in the pancreas and an increase of pancreas weight. Acinar cell vacuolization was evident in the pancreatic lobules, accompanied by some foci of pancreatic hemorrhage and marked peritoneal ascites. A pyknotic nucleus was in the center of necrotic acinar cell with a bright border. Taurocholic acid administration induced marked oedema, inflammatory cell infiltration and acinar cell necrosis^[1]^[2].
Biochemical Analysis: Taurocholic acid administration increased serum amylase and lipase activities^[1].

Correlated Product(s): Neuronostatin; Flavonoids 1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 145-42-6
Appearance Solid
Molecular Weight 537.68
Formula C₂₆H₄₄NNaO₇S
Color White to off-white
SMILES

C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
Synonyms

Sodium taurocholate; N-Choloyltaurine sodium
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (34)

All In Vivo Efficacy StudyWBELISAHistological Imaging/StainingIFRT-PCR

Sort by:

Journal Impact Factor

Nature

Structure and mechanism of the human bile acid transporter OSTα-OSTβ. [Abstract]

2026 Mar;651(8104):251-259. PMID: 41606314
Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jul;643(8070):192-200. [Abstract]

Taurocholic acid (TCA, 100 μM, 4 h) activated AMPK depending on the cAMP–Epac–MEK pathway in primary hepatocytes.
Science

Structure and function of the Arabidopsis ABC transporter ABCB19 in brassinosteroid export. [Abstract]

2024 Mar 22;383(6689):eadj4591. PMID: 38513023
Nat Commun

Structure and transport mechanism of the human prostaglandin transporter SLCO2A1. [Abstract]

2025 Aug 30;16(1):8124. PMID: 40885756
Microbiome

Maternal intestinal L. vaginalis facilitates embryo implantation and survival through enhancing uterine receptivity in sows. [Abstract]

2025 Jun 18;13(1):145. PMID: 40533850
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Plant Commun

Structural insights into brassinosteroid export mediated by the Arabidopsis ABC transporter ABCB1. [Abstract]

2025 Jan 13;6(1):101181. PMID: 39497419
Research (Wash D C)

Activation of Pancreatic Acinar FXR Protects against Pancreatitis via Osgin1-Mediated Restoration of Efficient Autophagy. [Abstract]

2022 Nov 2:2022:9784081. PMID: 36405253
Cancer Lett

Bile acid retention impairs tumoral antigen presentation and intrinsic tumor suppression in MASH-HCC. [Abstract]

2026 Aug 28:654:218589. PMID: 42173274
Adv Healthc Mater

Sodium Butyrate-Loaded Microspheres With Enhanced Bioavailability for Targeted Treatment of Intestinal Barrier Injury. [Abstract]

2025 Apr;14(9):e2402773. PMID: 39629540
Cell Death Discov

RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. [Abstract]

2025 Jul 23;11(1):338. PMID: 40702000
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
Proc Natl Acad Sci U S A

Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations. [Abstract]

2025 Dec 2;122(48):e2524436122. PMID: 41296732
Aging Cell

Human Umbilical Cord Plasma Metabolomics Uncover Potential Metabolites for Combating Aging. [Abstract]

2026 Jan;25(1):e70295. PMID: 41299210
Food Funct

Arachidonic acid enhances hepatocyte bile acid uptake and alleviates cholestatic liver disease by upregulating OATP1 expression. [Abstract]

2024 Sep 30;15(19):9916-9927. PMID: 39258405
Food Funct

Taurocholic acid ameliorates hypertension through the activation of TGR5 in the hypothalamic paraventricular nucleus. [Abstract]

2024 May 7;15(9):5088-5102. PMID: 38666497

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102. [Abstract]

Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced systolic blood pressure in spontaneously hypertensive rats.

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102. [Abstract]

Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced plasma levels of norepinephrine in spontaneously hypertensive rats.

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102. [Abstract]

Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced cardiomyocyte dilation (A-B) and fibrosis (C-D) in spontaneously hypertensive rats.

Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102. [Abstract]

Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced the average fluorescence intensity of DHE in cardiomyocytes of spontaneously hypertensive rats.
RSC Adv

Cytosolic β-glucosidase inhibition and renal blood flow suppression are leading causes for the enhanced systemic exposure of salidroside in hypoxic rats. [Abstract]

2018 Feb 23;8(16):8469-8483. PMID: 35539855
Int J Mol Sci

MGST1 Protects Pancreatic Ductal Cells from Inflammatory Damage in Acute Pancreatitis by Inhibiting Ferroptosis: Bioinformatics Analysis with Experimental Validation. [Abstract]

2025 Feb 22;26(5):1899. PMID: 40076525
Int Immunopharmacol

Detection of serum lactate dehydrogenase A and its metabolites on placental function in patients with intrahepatic cholestasis of pregnancy. [Abstract]

2025 Jan 3:145:113739. PMID: 39662271
Biomolecules

The Rabep1-Mediated Endocytosis and Activation of Trypsinogen to Promote Pancreatic Stellate Cell Activation. [Abstract]

2022 Jul 31;12(8):1063. PMID: 36008957
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
Sci Rep

Resveratrol improved mitochondrial biogenesis by activating SIRT1/PGC-1α signal pathway in SAP. [Abstract]

2024 Oct 31;14(1):26216. PMID: 39482340
Mol Cell Biochem

Bile acid-induced TBG depletion promotes trophoblast apoptosis via local thyroxine insufficiency in intrahepatic cholestasis of pregnancy. [Abstract]

2026 Jun 29. PMID: 42371391
Poult Sci

Molecular mechanisms of photoperiod regulation of bile acid metabolism in Taihe silky fowls based on the gut-liver axis. [Abstract]

2025 Jun 25;104(9):105489. PMID: 40592289
Biomedicines

The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia. [Abstract]

2025 Apr 4;13(4):874. PMID: 40299495
FASEB J

The metabolomic profiling identifies N, N-dimethylglycine as a facilitator of dorsal root ganglia neuron axon regeneration after injury. [Abstract]

2022 May;36(5):e22305. PMID: 35394692
Antiviral Res

A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid. [Abstract]

2019 Sep:169:104544. PMID: 31254557
Biochim Biophys Acta Mol Cell Biol Lipids

Integrated proteomic and metabolomic analysis reveals lipid metabolic dysregulation and ferroptosis as potential drivers of placental dysfunction in intrahepatic cholestasis of pregnancy. [Abstract]

2025 Oct 3;1871(1):159692. PMID: 41047095
J Pharm Biomed Anal

Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. [Abstract]

2025 Jul 15:259:116760. PMID: 40014894
Placenta

The role of ERp29/FOS/EMT pathway in excessive apoptosis of placental trophoblast cells in intrahepatic cholestasis of pregnancy. [Abstract]

2024 Mar 25:148:20-30. PMID: 38346375
Mol Reprod Dev

PIP2 Accumulation in the Spongiotrophoblast Drives Trophoblast Apoptosis in Intrahepatic Cholestasis of Pregnancy. [Abstract]

2026 Apr;93(4):e70105. PMID: 42017405
Research Square Preprint

2024 Feb 13.
Research Square Print

2022 Aug.
SSRN

2022 Jan 26.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (185.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (185.98 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8598 mL

9.2992 mL

18.5984 mL

5 mM

0.3720 mL

1.8598 mL

3.7197 mL

10 mM

0.1860 mL

0.9299 mL

1.8598 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (9.30 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Caiyun Wang, et al. Effects of taurocholic acid on immunoregulation in mice. Int Immunopharmacol. 2013 Feb;15(2):217-22. [Content Brief]

[2]. Xun Z,et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021 Feb;18(2):461-471. [Content Brief]

[3]. Glaser S, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis. 2010 Oct;42(10):709-17. [Content Brief]

[4]. Mo J, Yang A, et al. Neuronostatin ameliorates sodium taurocholate-induced acute pancreatitis in rats. Dig Dis Sci. 2013 Oct;58(10):2903-7. [Content Brief]

[5]. Du D, Yao L, et al. Protective effects of flavonoids from Coreopsis tinctoria Nutt. on experimental acute pancreatitis via Nrf-2/ARE-mediated antioxidant pathways. J Ethnopharmacol. 2018 Oct 5;224:261-272. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.8598 mL	9.2992 mL	18.5984 mL	46.4961 mL
	5 mM	0.3720 mL	1.8598 mL	3.7197 mL	9.2992 mL
	10 mM	0.1860 mL	0.9299 mL	1.8598 mL	4.6496 mL
	15 mM	0.1240 mL	0.6199 mL	1.2399 mL	3.0997 mL
	20 mM	0.0930 mL	0.4650 mL	0.9299 mL	2.3248 mL
	25 mM	0.0744 mL	0.3720 mL	0.7439 mL	1.8598 mL
	30 mM	0.0620 mL	0.3100 mL	0.6199 mL	1.5499 mL
	40 mM	0.0465 mL	0.2325 mL	0.4650 mL	1.1624 mL
	50 mM	0.0372 mL	0.1860 mL	0.3720 mL	0.9299 mL
	60 mM	0.0310 mL	0.1550 mL	0.3100 mL	0.7749 mL
	80 mM	0.0232 mL	0.1162 mL	0.2325 mL	0.5812 mL
	100 mM	0.0186 mL	0.0930 mL	0.1860 mL	0.4650 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Taurocholic acid sodium

34 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Taurocholic acid sodium

Bioactive Compound Library Max

Bioactive Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Food Additive Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Taurocholic acid sodium

All VEGFR Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Taurocholic acid sodium Related Classifications

HY-N0545 Related Classifications